GPCR and LLY Related Headlines
Go Back- Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows
- Bernstein on US Pharma and Biotech: Who might buy whom?
- Wolfe: 'We're observing some reports of GLP-1 users refreshing their wardrobes as weight loss progresses'
- Leerink on Structure Therapeutics (GPCR): 'Oral GLP-1 Achieves Best-In-Class Weight Loss'
- RBC: 'Our focus for LLY remains on the pending Orfo approval and subsequent launch'
